MultivisionDxTM
Skip to content

MULTIVISIONdx

Transforming cancer diagnostics

Spatial Biology for Personalized Medicine

We are developing decision-support tools for personalized diagnostics and therapy selection for solid tumors.

  • MultivisionDx™ is a machine learning computer-vision algorithm for high-throughput analysis of multiplex-stained tumor biopsies
  • Proof-of-concept in 650+ head-and-neck cancer patients (Punovuori et al 2024, Cell)
  • Patents pending for biomarker discovery platform and first-in-class compound biomarker for HNSCC
  • Biopsy

    Standard diagnostic biopsy and routine histology workflow
  • Sample Preparation

    Slide is treated with labeled antibodies
  • Scanning

    Multiplexed scanning
  • Spatial Analysis

    Machine learning algorithm assigns patient to one of known risk groups
  • Report

    A prognostic result is provided to the physician

Milestones

Media

A new imaging analysis method developed by researchers at the University of Helsinki offers a breakthrough in diagnosing head and neck cancers.

Using machine learning, the technique identifies individual cancer cell behaviors and tumor-tissue interactions, improving prognosis predictions and guiding personalized treatments. It could revolutionize diagnostics while remaining cost-effective.


University Of Helsinki

Read more
Uusi kuvantamisanalyysi mullistaa pään ja kaulan alueen syövän diagnostiikan

New method enables precise single-cell analysis of cancer and surrounding tissues, improving diagnosis and treatment predictions for head and neck cancer.

(article in Finnish)


STT INFO

Read more
Pään ja kaulan alueen syöpä iskee satoihin joka vuosi – Suomessa tehty merkittävä läpimurto

Leading Finnish tabloid ILTALEHTI reports on Multivision’s breakthrough cancer diagnostic tool. (article in Finnish)


ILTALEHTI

Read more
Comprehensive diagnosis of head and neck tumors

An international team of researchers led by Sara Wickström has now developed a new technique that allows the properties of cancer cells and their surrounding tissue to be analyzed in detail at the single-cell level.


Max Planck Institute Newsroom

Read more
Multivision Diagnostics - winner of the health and pharma pitching competition at Y Science 2023

Multivision Diagnostics takes the top spot in the Health and Pharma Pitching Competition at Y Science 2023, showcasing cutting-edge innovations shaping the future of healthcare.


University Of Helsinki

Read more
Multivision Diagnostics plans to transform cancer diagnostics and treatment

Multivision Diagnostics aims to revolutionize cancer diagnostics and treatment by developing advanced tools for more precise and personalized healthcare.


University Of Helsinki

Read more

We are MULTIVISIONdx

SARA WICKSTRÖM MD PhD

SARA WICKSTRÖM MD PhD Project Director

Professor, Director at Max Planck Institute for Molecular Biomedicine. World leader in stem cell and cancer research

Among “50 Scientists in the World Who Inspire” selected by Cell Press 2024. Innovation in Cell Biology Awardee 2023 by ASCB

MICHAEL WITTINGER PhD

MICHAEL WITTINGER PhD Business Advisor

Expert in business development in diagnostics and oncology

Serial entrepreneur in diagnostic software companies

KAROLINA PUNOVUORI PhD

Karolina Punovuori PhD Scientific Lead

Expert in tissue biology and professional science communicator

International research experience in top UK and Finnish Universities

FABIEN BERTILLOT PhD

Fabien Bertillot PhD Data Science Lead

Expert in computational cancer biology in academia and industry

Bridging computational cancer diagnostics in leading academic institutions and startups

JÁNOS LENGYEL

János Lengyel Software Lead

Expert in software development

Roles in software development in world leading companies (IBM, General Electric)

KATE MIROSHNIKOVA PhD

KATE MIROSHNIKOVA PhD Assay Development

Leader in tissue engineering research and computational image analyses

Research expertise in world leading institutions (Berkeley, USCF), principal investigator at NIH

Get in touch

We'll get back to you as soon as possible.